(Total Views: 322)
Posted On: 01/14/2021 2:08:57 PM
Post# of 36566
Once again due-diligence dealing with a Mammoth fund missed two target dates to transfer funds, Chinese are experts (smart) delaying progress but continue to have access to IP for 100k......
Generex business plan , since 2018, has not met expectations and Management is the blame. The picture looks worse,IMO, to keep the same CEO /Chairman of the board/President running both companies (GNBT/NGIO). it appears ego's could be involved. Any large fund investing in potential revenue/Management may decide NOT to commit unless proven results. If we had solid leadership with a successful track record raising funds would probably not be a big issue and it could expedite "complete vaccine" and other clinical trials!!! Since March many opportunities to capitalize but so far unable to reflect progress in pps.
Billions here Billions there .............how about a breakdown of the valuation to keep it simple???
Generex business plan , since 2018, has not met expectations and Management is the blame. The picture looks worse,IMO, to keep the same CEO /Chairman of the board/President running both companies (GNBT/NGIO). it appears ego's could be involved. Any large fund investing in potential revenue/Management may decide NOT to commit unless proven results. If we had solid leadership with a successful track record raising funds would probably not be a big issue and it could expedite "complete vaccine" and other clinical trials!!! Since March many opportunities to capitalize but so far unable to reflect progress in pps.
Billions here Billions there .............how about a breakdown of the valuation to keep it simple???
(1)
(1)
